🔗 Share this article

Given that the United States proceeds with historic adjustments to its vaccination recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by questioning COVID-19 vaccines throughout the global health crisis and has focused upon potential deaths after Covid immunization in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Agency leaders were set to announce major changes to the pediatric immunization program recently, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the world with insufficient data for benefit. The planned update has been delayed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US to become more similar to Denmark's approach, a society with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

The appointee has no obvious experience in drug development, approval processes or administrative roles, which has been typical for former directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Former heads of the center would “grasp legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Objectively, she lacks the type of experience that previous people who ran CBER have had.”

CDER has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and every single one have to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership component to the role, which oversees over 5,000 employees. “It is a huge management job, if you do it right,” she concluded.

Official Statement and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among agency officials on vaccines, a spokesperson said that the “inquiries rely on incorrect premises”.

“Her experience matches the duties of her role,” the spokesperson said, citing the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a controversial rapid medication authorization process that reportedly troubled her predecessors. “How are these drugs being selected for this fast-track system? Who takes the calls?” Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent regulations of most medications, aside from shots.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if concerning, track record, some experts have noted. She released a analysis using non-validated public submissions to estimate the frequency of heart inflammation following Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership featured altering rules for novel immunizations and ending “unnecessary” vaccines, she stated post-election on a online show. At the agency, Høeg has according to sources suggested preventing teenage boys from obtaining Covid vaccinations.

“She is an thorough ideologue who starts off with her beliefs and tailors the evidence to accommodate the evidence in a highly disingenuous, fraudulent way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other skeptics, {like|